Abstracts Archive - Page 1816 of 2607 - ACR Meeting Abstracts

Abstract Number: 4L • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials
Megan E. B. Clowse¹, Daniel J Wallace², Richard Furie³, Michelle Petri⁴, Marilyn Pike⁵, Piotr Leszczynski⁶, C Michael Neuwelt⁷, Kathryn Hobbs⁸, Mauro Keiserman⁹, Liliana Duca¹⁰, Kenneth Kalunian¹¹, Sabine Bongardt¹², Christian Stach¹², Carolyn Beaudot¹³, Brian Kilgallen¹³, Catrinel Galateanu¹⁴ and Caroline Gordon^15,16, ¹Rheumatology, Duke University, Durham, NC, ²Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³North Shore LIJ Health System, Manhasset, NY, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Med Pharm Consulting Inc, Cambridge, MA, ⁶Dept. of Rheumatology and Clinical Immunology, J. Strus Poznan Municipal Hospital, Poznan University of Medical Sciences, Poznan, Poland, ⁷Division of Rheumatology, Alameda County Medical Center, Oakland, CA, ⁸Denver Arthritis Clinic, Denver, CO, ⁹School of Medicine, Pontifical Catholic University, Porto Alegre, Brazil, ¹⁰Clinica Neomed, Brasov, Romania, ¹¹UCSD School of Medicine, La Jolla, CA, ¹²UCB Pharma, Monheim, Germany, ¹³UCB Pharma, Raleigh, NC, ¹⁴UCB Pharma, Brussels, Belgium, ¹⁵Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹⁶NIHR/Wellcome Trust Clinical Research Facility, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: In phase 2b trials, epratuzumab, a humanized anti-CD22 mAb that modulates B cell signaling without total B cell depletion, significantly improved disease activity in…
Abstract Number: 5L • 2015 ACR/ARHP Annual Meeting
Tofacitinib in Patients with Ankylosing Spondylitis: A Phase 2, 16-Week, Randomized, Placebo-Controlled, Dose-Ranging Study
Désirée van der Heijde¹, Atul A Deodhar², James C Wei³, Edit Drescher⁴, Dona Fleishaker⁵, Thijs Hendrikx⁶, David Li⁶, Sujatha Menon⁵ and Keith S Kanik⁵, ¹Dept. of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ³Division of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan, ⁴Csolnoky Ferenc Hospital, Veszprém, Hungary, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: This was the first investigation of the effects of tofacitinib (TOFA) in adult patients (pts) with active ankylosing spondylitis (AS). TOFA is an oral…
Abstract Number: 6L • 2015 ACR/ARHP Annual Meeting
Effect of Interleukin-17A Inhibition on Spinal Radiographic Changes through 2 Years in Patients with Active Ankylosing Spondylitis: Results of a Phase 3 Study with Secukinumab
Xenofon Baraliakos¹, Atul A. Deodhar², Jürgen Braun¹, Dominique Baeten³, Maxime Dougados⁴, Joachim Sieper⁵, Paul Emery⁶, Aimee Readie⁷, Ruvie Martin⁷, Shephard Mpofu⁸ and Hanno Richards⁸, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ³Clinical Immunology and Rheumatology, Academic Medical Center, Amsterdam, Netherlands, ⁴Hospital Cochin, Descartes Univ, Paris, France, ⁵University Hospital Charité, Berlin, Germany, ⁶NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland
Background/Purpose: In the MEASURE 1 trial (NCT01358175), secukinumab significantly improved the signs and symptoms of patients (pts) with active ankylosing spondylitis (AS) over 52 weeks…
Abstract Number: 7L • 2015 ACR/ARHP Annual Meeting
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Treatment Recommendations for Psoriatic Arthritis 2015
Laura C Coates^1,2, Arthur Kavanaugh³, Philip J. Mease⁴, Enrique R. Soriano⁵, M Laura Acosta-Felquer⁶, April W Armstrong⁷, Wilson Bautista-Molano⁸, Wolf-Henning Boehncke⁹, Willemina Campbell¹⁰, Alberto Cauli¹¹, Luis Espinoza¹², Oliver FitzGerald¹³, Dafna D. Gladman¹⁴, Alice B. Gottlieb¹⁵, Philip S. Helliwell², M. Elaine Husni¹⁶, Thorvardur Love^17,18, Ennio Lubrano¹⁹, Neil J McHugh²⁰, Peter Nash²¹, Alexis Ogdie-Beatty²², Ana-Maria Orbai²³, Andrew Parkinson²⁴, Denis O'Sullivan²⁵, Cheryl F Rosen²⁶, Sergio Schwartzman²⁷, Evan Siegel²⁸, Sergio Toloza²⁹, William Tuong³⁰ and Christopher T. Ritchlin³¹, ¹Medicine, University of Rochester, Rochester, NY, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³University of California San Diego, La Jolla, CA, ⁴Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁵Rheumatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷Keck School of Medicine, University of Southern California, Los Angeles, CA, ⁸Department of Rheumatology, Faculty of Medicine HMC/UMNG, Bogota, Colombia, Bogotá, Colombia, ⁹Department of Dermatology,, Geneva University Hospital, Geneva, Switzerland, ¹⁰Toronto Western Hospital, Toronto, ON, Canada, ¹¹University of Cagliari, Cagliari, Italy, ¹²Medicine-Section of Rheumatology, LSU Medical Center, New Orleans, LA, ¹³Department of Rheumatology, St. Vincent’s University Hospital, UCD School of Medicine and Medical Sciences and Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland, ¹⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁵Tufts Medical Center, Boston, MA, ¹⁶Rheumatology Dept A50, Cleveland Clinic, Cleveland, OH, ¹⁷Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹⁸Landspitali University Hospital, Reykjavík, Iceland, ¹⁹Cattedra di Reumatologia, Università del Molise, Campobasso, Italy, ²⁰Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²¹Department of Medicine, University of Queensland, Brisbane, Australia, ²²Medicine/Rheumatology, Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, ²³Rheumatology, Johns Hopkins University, Baltimore, MD, ²⁴Chapel Allerton Hospital, Leeds, United Kingdom, ²⁵St. Vincent’s University Hospital, Dublin, Ireland, ²⁶Division of Dermatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²⁷Rheumatology, Hospital for Special Surgery, New York, NY, ²⁸Arthritis & Rheumatism Assoc, Wheaton, MD, ²⁹Rheumatology, Ministry of Health, San Fernando del Valle de Catamarca, Argentina, ³⁰Department of Dermatology, University of California David, Davis, CA, ³¹Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Since the 2009 GRAPPA treatment recommendations were published, therapeutic options and management strategies for psoriatic arthritis (PsA) have advanced considerably. We updated and improved…
Abstract Number: 8L • 2015 ACR/ARHP Annual Meeting
A Phase III, Randomized, Double-Blind Clinical Study Comparing SB5, an Adalimumab Biosimilar, with Adalimumab Reference Product (Humira®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-week Results)
Michael E. Weinblatt¹, Asta Baranauskaite², Jaroslaw Niebrzydowski³, Eva Dokoupilova⁴, Agnieszka Zielinska⁵, Karina Sitek-Ziolkowska⁶, Janusz Jaworski⁷, Artur Racewicz⁸, Margarita Pileckyte², Krystyna Jedrychowicz-Rosiak⁹, Vyacheslav Zhdan¹⁰, Soo Yeon Cheong¹¹ and Jeehoon Ghil¹¹, ¹Brigham and Women’s Hospital, Boston, MA, ²Lithuanian University of Health Sciences, Kaunas, Lithuania, ³Medica Pro Familia, Gdynia, Poland, ⁴Medical Plus s.r.o., Uherske Hradiste, Czech Republic, ⁵Medica pro Familia, Warszawa, Poland, ⁶Medica pro Familia, Katowice, Poland, ⁷Reumatika Centrum Reumatologi, Warszawa, Poland, ⁸Zdrowie Osteo- Medic s.c, Bialystok, Poland, ⁹Mazowieckie Centrum Badañ Klinicznych, Grodzisk Mazowiecki, Poland, ¹⁰M.V.Sklifosovskyi Poltava Regional Clinical Hospital, Poltava, Ukraine, ¹¹Samsung Bioepis Co., Ltd., Incheon, South Korea
Background/Purpose: SB5 is a biologic agent developed as a biosimilar of the adalimumab reference product (ADL). Equivalence in pharmacokinetics (PK) between SB5 and ADL in…
Abstract Number: 9L • 2015 ACR/ARHP Annual Meeting
A Randomized Double-Blind Trial of Abatacept and Glucocorticoids for the Treatment of Giant Cell Arteritis
Carol A. Langford¹, David Cuthbertson², Steven R. Ytterberg³, Nader A. Khalidi⁴, Paul A. Monach⁵, Simon Carette⁶, Philip Seo⁷, Larry W. Moreland⁸, Michael Weisman⁹, Curry L. Koening¹⁰, Antoine G. Sreih¹¹, Robert F. Spiera¹², Carol McAlear¹³, Kenneth J. Warrington¹⁴, Christian Pagnoux⁶, Kathleen Maksimowicz-McKinnon¹⁵, Lindsy J. Forbess¹⁶, Gary S. Hoffman¹, Renee Borchin¹⁷, Jeffrey Krischer¹⁷ and Peter A. Merkel¹⁸, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ³Rheumatology Division, Mayo Clinic, Rochester, MN, ⁴McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Rheumatology, Boston University School of Medicine, Boston, MA, ⁶Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Johns Hopkins, Baltimore, MD, ⁸Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁹Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ¹¹Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹²Rheumatology, Hospital for Special Surgery, New York, NY, ¹³Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁴Rheumatology, Mayo Clinic, Rochester, MN, ¹⁵Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁷University of South Florida, Tampa, FL, ¹⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel primary systemic vasculitis. Although glucocorticoids are effective in treating GCA, they are associated with substantial toxicity and…
Abstract Number: 10L • 2015 ACR/ARHP Annual Meeting
Aiming for Remission in Rheumatoid Arthritis: Clinical and Radiographic Outcomes from a Randomized Controlled Strategy Trial Investigating the Added Value of Ultrasonography in a Treat-to-Target Regimen
Espen A. Haavardsholm¹, Anna-Birgitte Aga¹, Inge C Olsen², Hilde B. Hammer³, Till Uhlig⁴, Hallvard Fremstad⁵, Tor Magne Madland⁶, Åse S. Lexberg⁷, Hilde Haukeland⁸, Erik Rødevand⁹, Christian Høili¹⁰, Hilde Stray¹¹, Anne Noraas Bendvold¹², Inger Johanne Widding Hansen¹³, Gunnstein Bakland^14,15, Lena B. Nordberg¹, Siri Lillegraven¹, Désirée van der Heijde^1,16 and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Postboks 23 Vinderen, Diakonhjemmet Hospital, Oslo, Norway, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Dept. of Rheumatology, Ålesund Hospital, Helse Møre og Romsdal HF, Ålesund, Norway, ⁶Dept. of Rheumatology, Haukeland University Hospital, Bergen, Norway, ⁷Dept. of Rheumatology, Vestre Viken Hospital, Drammen, Norway, ⁸Dept. of Rheumatology, Martina Hansens Hospital, Bærum, Norway, ⁹Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, ¹⁰Dept. of Rheumatology, Hospital Østfold HF, Moss, Norway, ¹¹Haugesund Rheumatism Hospital, Haugesund, Norway, ¹²The Rheumatology Clinic Dovland/Bendvold, Kristiansand, Norway, ¹³Dept. of Rheumatology, Sørlandet Hospital, Kristiansand, Norway, ¹⁴Dept. of Rheumatology, University Hospital Northern Norway, Tromsø, Norway, ¹⁵Institute of Clinical Medicine, University Hospital of North Norway, Tromsø, Norway, ¹⁶Dept. of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The application of ultrasonography (US) in rheumatology clinical practice is growing. The ARCTIC trial (NCT01205854) was designed to examine if the use of a…
Abstract Number: 11L • 2015 ACR/ARHP Annual Meeting
Preliminary Results of a Double-Blind Randomised Trial of Rituximab Anti-B-Cell Therapy in Patients with Primary Sjogrens Syndrome
Simon Bowman¹, Colin Everett², Michele Bombardieri³, Robert Busch⁴, Paul Emery⁵, Frances Hall⁶, Colin T. Pease⁷, Costantino Pitzalis⁸, Elizabeth Price⁹, Luke Dawson¹⁰, Peter Smith¹¹, Nurhan Sutcliffe³, Wan-Fai Ng¹², Catherine Fernandez¹³, Sharon Ruddock¹³, Linda Sharples¹³, Catherine Reynolds¹³ and Sue Pavitt¹⁴, ¹Rheumatology Dept, University Hospital Birmingham, Birmingham, United Kingdom, ²Leeds Institute for Clinical Trials Research, University of Leeds, LEEDS, United Kingdom, ³Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, ⁴Department of Life Sciences, University of Roehampton, London, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds Gen Infirmary, Leeds, United Kingdom, ⁶School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom, ⁷Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁸Centre for Experimental Medicine & Rheumatology, Queen Mary's School of Medicine and Dentistry, London, United Kingdom, ⁹Rheumatology Department, Great Western Hospital, Swindon, United Kingdom, ¹⁰School of Dental Sciences, University of Liverpool,, Liverpool, United Kingdom, ¹¹School of Dental Sciences,, University of Liverpool, Liverpool, United Kingdom, ¹²NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, United Kingdom, ¹³Leeds Institute for Clinical Trials Research, University of Leeds, Leeds, United Kingdom, ¹⁴Division of Applied Health & Clinical Translation , School of Dentistry, University of Leeds, Leeds, United Kingdom
Background/Purpose: Evidence from open-label and observational studies support anti-B-cell therapy in patients with primary Sjogren’s Syndrome (PSS). The TRACTISS trial aimed to determine the extent…
Abstract Number: 12L • 2015 ACR/ARHP Annual Meeting
Assessment of Immunogenicity of Live Zoster Vaccination (Zostavax®) in Rheumatoid Arthritis Patients on Background Methotrexate before and after Initiating Tofacitinib or Placebo
Kevin Winthrop IV¹, Ann Wouters², Ernest H. Choy³, Koshika Soma², Jennifer Hodge², Chudy Nduaka², Pinaki Biswas², Lisa K. McNeil², Sherry Passador², Christopher F. Mojcik² and William F.C. Rigby⁴, ¹Oregon Health and Sciences University, Portland, OR, ²Pfizer Inc, New York, NY, ³CREATE Center, Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁴Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Clinical guidelines recommend using live zoster vaccine (LZV) to prevent…
Abstract Number: 13L • 2015 ACR/ARHP Annual Meeting
Safety and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study in Rheumatoid Arthritis
Yoshiya Tanaka¹, Tsutomu Takeuchi², Hisanori Umehara³, Toshihiro Nanki⁴, Hideto Akama⁵, Nobuyuki Yasuda⁵, Fumitoshi Tago⁵, Makoto Kawakubo⁵, Seiichiro Hojo⁵, Tetsu Kawano⁶ and Toshio Imai⁶, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Dept. of Internal Medicine, School of Medicine Keio University, Tokyo, Japan, ³Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁵EISAI Co. Ltd., Tokyo, Japan, ⁶KAN Research Institute, Inc., Kobe, Japan
Background/Purpose: Fractalkine (CX3CL1, designated as FKN hereafter) is the sole member of the CX3C-chemokine which leads to dual actions, chemotaxis and cell adhesion for leukocytes…
Abstract Number: 14L • 2015 ACR/ARHP Annual Meeting
Safety and Efficacy of ABT-494, a Novel Selective JAK1 Inhibitor, in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Anti-TNF Biologic Therapy
Joel M. Kremer¹, Edward C. Keystone², Paul Emery³, Heidi S. Camp⁴, Alan Friedman⁴, Li Wang⁴, Ahmed A. Othman⁴, Nasser Khan⁴ and Steven Jungerwirth⁴, ¹Albany Medical College, Albany, NY, ²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: The safety, efficacy, and dose response of ABT-494, a novel selective JAK1 inhibitor, were characterized vs placebo (PBO) in patients (pts) with moderately to…
Abstract Number: 15L • 2015 ACR/ARHP Annual Meeting
Identification of Four-and-a-Half-LIM Domain 1 (FHL1) As a New Autoantibody Target in Idiopathic Inflammatory Myopathies
Inka Albrecht¹, Cecilia Wick¹, Åsa Hallgren², Anna Tjärnlund¹, Kanneboyina Nagaraju³, Felipe Andrade⁴, Kathryn Thompson⁵, William Coley⁵, Aditi Phadke⁶, Lina-Marcela Diaz-Gallo¹, Matteo Bottai⁷, Inger Nennesmo⁸, Karine Chemin⁹, Jessica Herrath¹⁰, Karin Johansson¹, Anders Wikberg¹, Jimmy Ytterberg¹, Roman Zubarev¹, Olof Danielsson¹¹, Olga Krystufkova¹², Jiri Vencovsky¹³, Nils Landegren², Marie Wahren-Herlenius¹⁴, Leonid Padyukov¹⁵, Olle Kämpe² and Ingrid E. Lundberg¹⁶, ¹Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Experimental Endocrinology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ³The George Washington University Medical Center, Children's National Medical Center, Washington, DC, ⁴Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Children's National Medical Center, Washington, DC, ⁶Research Center for Genetic Medicine, Children's National Medical Center, Washington, DC, ⁷Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁸Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden, ⁹Medicine, Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ¹⁰Department of Medicine,, Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ¹¹Department of Clinical and Experimental Medicine, Division of Neurology, Faculty of Health Sciences, Linköping University, Linköping, Sweden, ¹²Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ¹³Rheumatology, Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ¹⁴Department of Medicine, Experimental Rheumatology Unit, Solna, Sweden, ¹⁵Department of medicine, Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ¹⁶Karolinska University Hospital, Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of rare systemic autoimmune diseases collectively called myositis causing progressive muscle weakness. Interestingly, myositis-specific autoantibodies described…
Abstract Number: 2445 • 2015 ACR/ARHP Annual Meeting
Development and Usability Testing of an Ipad-Based Psycho-Educational Game for Children with Juvenile Idiopathic Arthritis and Their Parents
Jennifer N. Stinson¹, Adam M. Huber², Mark Connelly³, Nadia Luca⁴, Lynn R. Spiegel⁵, Argerie Tsimicalis⁶, Stephanie Luca⁷, Roberta Berard⁸, Julie Barsalou⁹, Sarah Campillo¹⁰, Paul Dancey¹¹, Ciarán M. Duffy¹², Brian Feldman¹³, Nicole Johnson⁴, Patrick McGrath¹⁴, Natalie J. Shiff¹⁵, Shirley M Tse¹⁶, Lori B. Tucker¹⁷ and J. Charles Victor¹⁸, ¹Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada, ²Pediatric rheumatology, IWK Health Centre, Halifax, NS, Canada, ³Psychology, University of Kansas Medical Center, Kansas City, KS, ⁴Pediatrics/Alberta Children's Hospital, Department of Pediatrics/University of Calgary, Calgary, AB, Canada, ⁵Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ⁶McGill University, Montreal, QC, Canada, ⁷The Hospital for Sick Children, Toronto, ON, Canada, ⁸Children's Hospital of Western Ontario, London, ON, Canada, ⁹CHU Sainte-Justine, Université de Montréal, Montreal, QC, Canada, ¹⁰Rheumatology, Montreal Children's Hospital, Montreal, QC, Canada, ¹¹Health Science Centre, Memorial University of Newfoundland, St Johns, NF, Canada, ¹²Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ¹³Division of Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ¹⁴IWK Health Centre, Halifax, NS, Canada, ¹⁵Pediatric Rheumatology, University of Saskatchewan, Saskatoon, SK, Canada, ¹⁶Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁷Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, ¹⁸University of Toronto, Toronto, ON, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a common chronic childhood illness that can negatively impact health-related quality of life (HRQL). In younger years, children manage…
Abstract Number: 2446 • 2015 ACR/ARHP Annual Meeting
Synovial Fluid Proteins Differentiate Patients with Oligoarticular Juvenile Idiopathic Arthritis Who Are Destined to Extend from Those Who Will Remain Persistent in Course
AnneMarie C. Brescia¹, Megan M. Simonds², Kathleen E. Sullivan³ and Carlos D. Rose⁴, ¹Pediatric Rheumatology, Nemours A.I. duPont Hospital for Children, Wilmington, DE, ²Nemours Research, Nemours/AI duPont Hospital for Children, Wilmington, DE, ³Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Pediatrics, Nemours A.I. duPont Hospital for Children, Division of Pediatric Rheumatology, Thomas Jefferson University, Wilmington, DE
Background/Purpose: Children with oligoarticular juvenile idiopathic arthritis (JIA) who have an extended course (recruitment of 5 or more joints after 6 months of disease) have…
Abstract Number: 2447 • 2015 ACR/ARHP Annual Meeting
The Juvenile Arthritis Disease Activity Score Remains the Disease Activity Marker of Choice for Adults with Polyarticular Juvenile Idiopathic Arthritis
Qiong Wu¹, Nicola Ambrose^1,2,3, Debajit Sen^1,2,3, Maria J. Leandro⁴, Charlotte Wing², Nicola Daly², Kate Webb^1,2, Corinne Fisher^1,2, Linda Suffield¹, Francesca Josephs¹, Clarissa Pilkington³, Despina Eleftheriou^1,3, Muthana Al-Obaidi³, Sandrine Compeyrot-Lacassagne³, Lucy R Wedderburn^1,3 and Yiannis Ioannou^1,2,3, ¹Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ²Adolescent Rheumatology Department, University College London Hospital NHS Trust, London, United Kingdom, ³Paediatric Rheumatology Department, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁴Centre for Rheumatology and Bloomsbury Rheumatology Unit, University College London, London, United Kingdom
Background/Purpose: A considerable proportion of children with polyarticular juvenile idiopathic arthritis (polyJIA) continue to experience active disease into adulthood. There is no validated disease activity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].